Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims for Grail, Inc. investors regarding losses that may be recoverable under federal securities laws following the company's failure to meet clinical trial endpoints [1][1]. Group 1: Investigation Details - The investigation focuses on Grail's executive officers and their compliance with federal securities laws [1]. - Grail disclosed on February 19, 2026, that its NHS-Galleri trial did not achieve its primary clinical endpoint, leading to a significant decline of approximately 48% in share price during after-hours trading [1][1]. Group 2: Investor Information - Investors who purchased Grail securities and suffered losses are encouraged to join the investigation without any cost or obligation [1]. - Contact information for inquiries includes Jim Baker at (619) 814-4471 or via email [1]. Group 3: Johnson Fistel Overview - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights and securities class action lawsuits, with a history of recovering approximately $90.725 million for clients [1][1]. - The firm has been ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services in 2024, marking its eighth recognition as a top plaintiffs' securities law firm in the U.S. [1].